arsenic has been researched along with melphalan in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (14.29) | 18.7374 |
| 1990's | 1 (7.14) | 18.2507 |
| 2000's | 8 (57.14) | 29.6817 |
| 2010's | 3 (21.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Frei, H; Tripathy, NK; Würgler, FE | 1 |
| Grünwald, HW; Rosner, F | 1 |
| KNOCK, FE | 1 |
| Berenson, JR; Ferretti, D; Purner, MB; Swift, RA | 1 |
| Berenson, JR; Borad, MJ; Swift, R | 1 |
| Anderson, KC; Hideshima, T; Richardson, PG; Schlossman, R | 1 |
| Gokhalé, P; Morrison, MJ; Patel, T; Vissers, MC | 1 |
| Berenson, JR; Bessudo, A; Boccia, R; Bozdech, M; Ferretti, D; Flam, M; Jilani, S; Louie, R; Lutzky, J; Moss, R; Patel, R; Russell, K; Siegel, D; Stadtmauer, E; Steis, R; Swift, RA; Talisman Pomeroy, J; Volk, J; Wong, SF; Yeh, HS | 1 |
| Baritaki, S; Berenson, JR; Bonavida, B; Campbell, RA; Chen, H; Gordon, M; Pang, S; Said, J; Sanchez, E; Shalitin, D; Steinberg, JA; Wang, C | 1 |
| Meng, H; Qian, W; Shao, K; Yang, C; Yang, X; Ye, X; Zhou, Y | 1 |
| Alousi, A; Anderlini, P; Champlin, RE; Giralt, S; Hosing, C; Jones, RB; Khan, FB; Mendoza, F; Nieto, Y; Parikh, G; Pelosini, M; Popat, U; Qazilbash, MH; Saliba, RM; Wang, M; Weber, DM | 1 |
| Bashir, Q; Bassett, RL; Champlin, RE; Giralt, SA; Hosing, CM; Khan, H; Orlowski, RZ; Parmar, S; Popat, UR; Qazilbash, MH; Shah, JJ; Shah, N; Sharma, M; Thall, PF; Wang, M | 1 |
| Boise, LH; Cai, Y; Lee, KP; Matulis, SM; Morales, AA; Yehiayan, L | 1 |
| Du, J; Fan, J; Fu, W; He, J; Hou, J; Li, R; Liu, S; Liu, X; Qu, Y; Xi, H; Yan, W; Yang, J; Zhang, C | 1 |
3 review(s) available for arsenic and melphalan
| Article | Year |
|---|---|
Cytotoxic drugs and leukaemogenesis.
Topics: Adult; Aged; Arsenic; Benzene; Bone Marrow; Breast Neoplasms; Female; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Lymphoma; Male; Melphalan; Middle Aged; Multiple Myeloma; Mycosis Fungoides; Ovarian Neoplasms; Paraproteinemias; Waldenstrom Macroglobulinemia | 1980 |
NEWER ANTICANCER AGENTS.
Topics: Alkylating Agents; Antineoplastic Agents; Arsenicals; Cyclophosphamide; Dactinomycin; Fluorouracil; Humans; Mechlorethamine; Melphalan; Methotrexate; Mitomycin; Mitomycins; Neoplasms; Pharmacology; Steroids; Triethylenemelamine; Vinblastine; Vincristine | 1964 |
New treatments for multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Boronic Acids; Bortezomib; Clinical Trials as Topic; Dexamethasone; Humans; Lenalidomide; Melphalan; Multiple Myeloma; Oxides; Pyrazines; Thalidomide | 2005 |
4 trial(s) available for arsenic and melphalan
| Article | Year |
|---|---|
A prospective, open-label safety and efficacy study of combination treatment with melphalan, arsenic trioxide, and ascorbic acid in patients with relapsed or refractory multiple myeloma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Disease Progression; Drug Resistance, Neoplasm; Humans; Melphalan; Middle Aged; Multiple Myeloma; Oxides; Prospective Studies; Recurrence; Time Factors; Treatment Outcome | 2004 |
Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single-arm study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Creatinine; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Oxides; Prospective Studies; Recurrence; Survival Analysis; Treatment Outcome | 2006 |
Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial.
Topics: Adult; Aged; Antineoplastic Agents; Antioxidants; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Oxides; Survival Rate; Time Factors; Transplantation Conditioning; Transplantation, Autologous | 2008 |
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Blood Transfusion, Autologous; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Oxides; Prognosis; Pyrazines; Transplantation Conditioning | 2012 |
7 other study(ies) available for arsenic and melphalan
| Article | Year |
|---|---|
Genetic toxicity of six carcinogens and six non-carcinogens in the Drosophila wing spot test.
Topics: Aminobiphenyl Compounds; Amitrole; Animals; Arsenates; Arsenic; Arsenites; Carcinogens; Chlorambucil; Drosophila melanogaster; Genes, Recessive; Melphalan; Mutagenicity Tests; Mutagens; Phenotype; Sodium Compounds | 1990 |
Efficacy of melphalan, arsenic trioxide, and ascorbic acid combination therapy (MAC) in relapsed and refractory multiple myeloma.
Topics: Aged; Antineoplastic Agents, Alkylating; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Oxides; Recurrence; Treatment Outcome | 2005 |
The effect of intracellular ascorbate on the susceptibility of HL60 and Jurkat cells to chemotherapy agents.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Caspases; Cell Count; Dehydroascorbic Acid; Drug Resistance, Neoplasm; Etoposide; HL-60 Cells; Humans; Jurkat Cells; Melphalan; Oxides | 2006 |
Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; Immunoglobulin G; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Oxides; Pyrazines; Xenograft Model Antitumor Assays | 2007 |
Refractory multiple myeloma treated with homoharringtonine: report of two cases.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carmustine; Cyclophosphamide; Dexamethasone; Doxorubicin; Harringtonines; Homoharringtonine; Humans; Male; Melphalan; Multiple Myeloma; Oxides; Prednisone; Remission Induction; Salvage Therapy; Thalidomide; Vincristine; Vindesine | 2007 |
Alterations in glutathione levels and apoptotic regulators are associated with acquisition of arsenic trioxide resistance in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Glutathione; Humans; Melphalan; Minor Histocompatibility Antigens; Multiple Myeloma; Oxides; Phenotype; Proto-Oncogene Proteins c-bcl-2 | 2012 |
MicroRNA-451 regulates stemness of side population cells via PI3K/Akt/mTOR signaling pathway in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzopyrans; Blotting, Western; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Melphalan; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Multiple Myeloma; Neoplastic Stem Cells; Oxides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; Side-Population Cells; Signal Transduction; TOR Serine-Threonine Kinases; Transplantation, Heterologous; Tuberous Sclerosis | 2015 |